Bionomics IPO Presentation Deck

Wholly-Owned Collaboration Focused CNS Pipeline with Multiple Potential Catalysts on the Horizon PROGRAM BNC210 a7 receptor NAM EmpathBio BNC210 MERCK COLLABORATION a7 receptor PAM PRECLINICAL PHASE 1 Post-Traumatic Stress Disorder (PTSD) ATTUNE Study 200 patients, -25 centers in US Social Anxiety Disorder (SAD) PREVAIL 150 patients, -15 centers in US PHASE 2 +MDMA derivative Memorandum of Understanding to explore EMP-01 (PTSD) combination treatment regimen for PTSD 2 candidates for cognitive deficits in Alzheimer's Disease NAM Allosteric Modulator Bionomics PAM-Positive Allesteric Modulator PHASE 3 EXPECTED TIMING Study underway Topline Data: 1H'23 Starting Ph2: YE'21 Topline Data: YE'22 Ongoing Ph1 Safety & biomarker studies ongoing 6

View entire presentation